146 related articles for article (PubMed ID: 34865105)
1. Preoperative and postoperative prognostic factors of patients with stage II/III lower rectal cancer without neoadjuvant therapy in the clinical trial (JCOG0212).
Ohue M; Fujita S; Mizusawa J; Kanemitsu Y; Hamaguchi T; Tsukamoto S; Noura S; Yasui M; Itoh M; Shiomi A; Komori K; Watanabe J; Akazai Y; Shiozawa M; Yamaguchi T; Bandou H; Katsumata K; Moriya Y
Jpn J Clin Oncol; 2022 Feb; 52(2):114-121. PubMed ID: 34865105
[TBL] [Abstract][Full Text] [Related]
2. Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trial.
Fujita S; Akasu T; Mizusawa J; Saito N; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Shiozawa M; Yamaguchi T; Moriya Y;
Lancet Oncol; 2012 Jun; 13(6):616-21. PubMed ID: 22591948
[TBL] [Abstract][Full Text] [Related]
3. Predictive factors of pathological lateral pelvic lymph node metastasis in patients without clinical lateral pelvic lymph node metastasis (clinical stage II/III): The analysis of data from the clinical trial (JCOG0212).
Komori K; Fujita S; Mizusawa J; Kanemitsu Y; Ito M; Shiomi A; Ohue M; Ota M; Akazai Y; Shiozawa M; Yamaguchi T; Bandou H; Katsumata K; Kinugasa Y; Takii Y; Akasu T; Moriya Y;
Eur J Surg Oncol; 2019 Mar; 45(3):336-340. PubMed ID: 30477950
[TBL] [Abstract][Full Text] [Related]
4. [A single center retrospective study on surgical efficacy of T3NxM0 middle-low rectal cancer without neoadjuvant therapy].
Liu P; Lou Z; Mei Z; Gao X; Hao L; Liu L; Gong H; Meng R; Yu E; Wang H; Wang H; Zhang W
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):66-72. PubMed ID: 30703796
[TBL] [Abstract][Full Text] [Related]
5. Number of lymph nodes examined and prognosis among pathologically lymph node-negative patients after preoperative chemoradiation therapy for rectal adenocarcinoma.
Tsai CJ; Crane CH; Skibber JM; Rodriguez-Bigas MA; Chang GJ; Feig BW; Eng C; Krishnan S; Maru DM; Das P
Cancer; 2011 Aug; 117(16):3713-22. PubMed ID: 21328329
[TBL] [Abstract][Full Text] [Related]
6. Urinary dysfunction after rectal cancer surgery: Results from a randomized trial comparing mesorectal excision with and without lateral lymph node dissection for clinical stage II or III lower rectal cancer (Japan Clinical Oncology Group Study, JCOG0212).
Ito M; Kobayashi A; Fujita S; Mizusawa J; Kanemitsu Y; Kinugasa Y; Komori K; Ohue M; Ota M; Akazai Y; Shiozawa M; Yamaguchi T; Akasu T; Moriya Y;
Eur J Surg Oncol; 2018 Apr; 44(4):463-468. PubMed ID: 29428473
[TBL] [Abstract][Full Text] [Related]
7. Selective lateral lymph node dissection after neoadjuvant chemoradiotherapy in rectal cancer.
Chen JN; Liu Z; Wang ZJ; Mei SW; Shen HY; Li J; Pei W; Wang Z; Wang XS; Yu J; Liu Q
World J Gastroenterol; 2020 Jun; 26(21):2877-2888. PubMed ID: 32550762
[TBL] [Abstract][Full Text] [Related]
8. Lateral pelvic lymph node dissection after neoadjuvant chemo-radiation for preoperative enlarged lateral nodes in advanced low rectal cancer: study protocol for a randomized controlled trial.
Wei M; Wu Q; Fan C; Li Y; Chen X; Zhou Z; Han J; Wang Z
Trials; 2016 Nov; 17(1):561. PubMed ID: 27884204
[TBL] [Abstract][Full Text] [Related]
9. Mesorectal Excision With or Without Lateral Lymph Node Dissection for Clinical Stage II/III Lower Rectal Cancer (JCOG0212): A Multicenter, Randomized Controlled, Noninferiority Trial.
Fujita S; Mizusawa J; Kanemitsu Y; Ito M; Kinugasa Y; Komori K; Ohue M; Ota M; Akazai Y; Shiozawa M; Yamaguchi T; Bandou H; Katsumata K; Murata K; Akagi Y; Takiguchi N; Saida Y; Nakamura K; Fukuda H; Akasu T; Moriya Y;
Ann Surg; 2017 Aug; 266(2):201-207. PubMed ID: 28288057
[TBL] [Abstract][Full Text] [Related]
10. Local recurrences in western low rectal cancer patients treated with or without lateral lymph node dissection after neoadjuvant (chemo)radiotherapy: An international multi-centre comparative study.
Kroon HM; Malakorn S; Dudi-Venkata NN; Bedrikovetski S; Liu J; Kenyon-Smith T; Bednarski BK; Ogura A; van de Velde CJH; Rutten HJT; Beets GL; Thomas ML; Kusters M; Chang GJ; Sammour T
Eur J Surg Oncol; 2021 Sep; 47(9):2441-2449. PubMed ID: 34120810
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of Laparoscopic Total Mesorectal Excision with Extended Lateral Pelvic Lymph Node Dissection for Advanced Lower Rectal Cancer after Preoperative Chemoradiotherapy.
Ogura A; Akiyoshi T; Nagasaki T; Konishi T; Fujimoto Y; Nagayama S; Fukunaga Y; Ueno M; Kuroyanagi H
World J Surg; 2017 Mar; 41(3):868-875. PubMed ID: 27730352
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of the randomized trial of mesorectal excision with or without lateral lymph node dissection in rectal cancer (JCOG0212).
Tsukamoto S; Fujita S; Ota M; Mizusawa J; Shida D; Kanemitsu Y; Ito M; Shiomi A; Komori K; Ohue M; Akazai Y; Shiozawa M; Yamaguchi T; Bando H; Tsuchida A; Okamura S; Akagi Y; Takiguchi N; Saida Y; Akasu T; Moriya Y;
Br J Surg; 2020 Apr; 107(5):586-594. PubMed ID: 32162301
[TBL] [Abstract][Full Text] [Related]
13. [Thirty years' changes of the strategy of lateral lymph node dissection in low rectal cancer: treatment experience and prognostic analysis of 289 cases in one single center].
Tang JQ; Li HY; Liu T; Zhang JL; Zuo S; Sun L; Wu YC; Jiang Y; Chen GW; Wu T; Wan YL; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Oct; 24(10):889-896. PubMed ID: 34674464
[No Abstract] [Full Text] [Related]
14. Lymph node ratio is an independent prognostic factor in node positive rectal cancer patients treated with preoperative chemoradiotherapy followed by curative resection.
Zeng WG; Zhou ZX; Wang Z; Liang JW; Hou HR; Zhou HT; Zhang XM; Hu JJ
Asian Pac J Cancer Prev; 2014; 15(13):5365-9. PubMed ID: 25041003
[TBL] [Abstract][Full Text] [Related]
15. Importance of the circumferential extent of tumors and clinical lymph node status as prognostic factors after preoperative chemoradiotherapy and surgery in patients with rectal cancer.
Yoon WS; Park W; Choi DH; Ahn YC; Chun HK; Lee WY; Yun SH; Kang WK; Lim HY; Park YS
Tumori; 2010; 96(4):568-76. PubMed ID: 20968136
[TBL] [Abstract][Full Text] [Related]
16. The effect of preoperative chemoradiotherapy on lymph nodes harvested in TME for rectal cancer.
Scabini S; Montecucco F; Nencioni A; Zoppoli G; Sartini M; Rimini E; Massobrio A; De Marini L; Poggi A; Boaretto R; Romairone E; Ballestrero A; Ferrando V
World J Surg Oncol; 2013 Nov; 11():292. PubMed ID: 24246069
[TBL] [Abstract][Full Text] [Related]
17. Effect of lateral lymph node dissection for mid and low rectal cancer: An ad-hoc analysis of the ACTS-RC (JFMC35-C1) randomized clinical trial.
Oki E; Shimokawa M; Ando K; Murata A; Takahashi T; Maeda K; Kusumoto T; Munemoto Y; Nakanishi R; Nakashima Y; Saeki H; Maehara Y
Surgery; 2019 Mar; 165(3):586-592. PubMed ID: 30314724
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of residual lateral lymph node metastasis after neoadjuvant (chemo)radiotherapy in patients with advanced low rectal cancer.
Akiyoshi T; Toda S; Tominaga T; Oba K; Tomizawa K; Hanaoka Y; Nagasaki T; Konishi T; Matoba S; Fukunaga Y; Ueno M; Kuroyanagi H
BJS Open; 2019 Dec; 3(6):822-829. PubMed ID: 31832589
[TBL] [Abstract][Full Text] [Related]
19. The total number of lymph nodes harvested from pathological T3N0 rectal cancer patients: Prognostic significance and potential indication for postoperative radiotherapy.
Xiao WW; Zhang LN; You KY; Huang R; Yu X; Chang H; Ding PR; Gao YH
J Cancer Res Ther; 2018 Jun; 14(Supplement):S288-S294. PubMed ID: 29970678
[TBL] [Abstract][Full Text] [Related]
20. Monthly tegafur-uracil maintenance for increasing relapse-free survival in ypStage III rectal cancer patients after preoperative radiotherapy, radical resection, and 12 postoperative chemotherapy cycles: a retrospective study.
Kuo YH; Lai CH; Huang CY; Chen CJ; Huang YC; Huang WS; Chin CC
BMC Cancer; 2019 Aug; 19(1):815. PubMed ID: 31419963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
